"Patients with metastatic hormone-sensitive prostate cancer benefited from treatment with darolutamide plus ADT and docetaxel ...

The pCR was 37.3% (95% CI, 33.2-41.6) in the durvalumab arm and 27.5% (95% CI, 23.8-31.6) in the comparator arm.

Casdatifan showed promising clinical activity in clear cell RCC, with response rates between 25% and 33% across dosage cohorts. The 100 mg/day dosage of casdatifan is planned for future combination ...

A total of 37 studies included real-world OS as an outcome; in these studies, median real-world OS ranged from 9 months to 23.5 months.

Radium-223 re-treatment in mCRPC patients shows a low incidence of hematologic and non-hematologic adverse events, including skeletal-related events. The study reported a median overall survival of 16 ...

Darolutamide plus ADT significantly improves radiological progression-free survival in mHSPC, reducing progression or death risk by 46%. The treatment effect is more pronounced in low-volume disease, ...

"The efficacy findings reported to date are 71% any time response," says John A. Taylor III, MD, MS. In this video, John A. Taylor III, MD, MS, shares the design and preliminary findings of the phase ...

Nadofaragene firadenovec shows high efficacy in BCG-unresponsive NMIBC, with 79% achieving complete response at three months. The study reported a favorable safety profile, with no grade 4-5 adverse ...

"The median progression-free survival and median overall survival continue to be almost double what we see with chemotherapy," says Gopa Iyer, MD. In this video, Gopa Iyer, MD, shares findings from an ...

"I think this is the next step for testing the clinical activity of this agent," says David A. Braun, MD, PhD. In this video, David A. Braun, MD, PhD, describes background and design of the phase 2 ...

“Interestingly, the confirmed response rate in the intention to treat population was 32%, but this increases to 53% in the MET driven subset,” says Francesca Jackson-Spence, MBChB, BMedSc, MRCP. In ...